Characteristics of therapy
| Treatment . | CP (n = 1148) . | AP (n = 175) . | BP (n = 246) . | < 1975 (n = 140) . | 1975-1982 (n = 164) . | 1983-1990 (n = 230) . | 1991-2000 (n = 492) . | > 2000 (n = 543) . |
|---|---|---|---|---|---|---|---|---|
| Hydroxyurea or busulfan, n (%) | 138 (12) | 31 (17) | 2 (< 1) | 100 (71) | 37 (22) | 5 (2) | 23 (5) | 4 (< 1) |
| IFN-α based, n (%) | 430 (38) | 47 (27) | 8 (3) | 0 | 16 (10) | 152 (66) | 316 (64) | 2 (< 1) |
| Single agents, n (%) | 8 (< 1%) | 9 (5) | 34 (14) | 10 (7) | 2 (1) | 4 (2) | 29 (6) | 6 (1) |
| Cytarabine ± other, n (%) | 97 (8) | 27 (15) | 55 (22) | 26 (19) | 94 (57) | 38 (16) | 18 (4) | 3 (< 1) |
| Combination chemotherapy, n (%) | 1 (< 1) | 2 (1) | 42 (17) | 1 (< 1) | 10 (6) | 17 (7) | 16 (3) | 1 (< 1) |
| Allogeneic stem cell transplantation, n (%) | 16 (1) | 5 (3) | 1 (< 1) | 0 | 0 | 1 (< 1) | 20 (4) | 1 (< 1) |
| Tyrosine kinase inhibitor, n (%) | 420 (37) | 50 (29) | 65 (26) | 0 | 0 | 0 | 36 (7) | 499 (92) |
| No therapy, n (%) | 1 (< 1) | 7 (3) | 0 | 0 | 1 | 1 | 6 (1) | |
| Unknown/not available, n (%) | 37 (3) | 3 (2) | 32 (13) | 2 (1) | 4 (2) | 12 (5) | 33 (7) | 21 (4) |
| Stem cell transplantation salvage by CML phase at time of transplantation, n (%)* | 74 (39) | 42 (22) | 75 (39) | 0 | 2 (1) | 28 (15) | 114 (60) | 47 (25) |
| Treatment . | CP (n = 1148) . | AP (n = 175) . | BP (n = 246) . | < 1975 (n = 140) . | 1975-1982 (n = 164) . | 1983-1990 (n = 230) . | 1991-2000 (n = 492) . | > 2000 (n = 543) . |
|---|---|---|---|---|---|---|---|---|
| Hydroxyurea or busulfan, n (%) | 138 (12) | 31 (17) | 2 (< 1) | 100 (71) | 37 (22) | 5 (2) | 23 (5) | 4 (< 1) |
| IFN-α based, n (%) | 430 (38) | 47 (27) | 8 (3) | 0 | 16 (10) | 152 (66) | 316 (64) | 2 (< 1) |
| Single agents, n (%) | 8 (< 1%) | 9 (5) | 34 (14) | 10 (7) | 2 (1) | 4 (2) | 29 (6) | 6 (1) |
| Cytarabine ± other, n (%) | 97 (8) | 27 (15) | 55 (22) | 26 (19) | 94 (57) | 38 (16) | 18 (4) | 3 (< 1) |
| Combination chemotherapy, n (%) | 1 (< 1) | 2 (1) | 42 (17) | 1 (< 1) | 10 (6) | 17 (7) | 16 (3) | 1 (< 1) |
| Allogeneic stem cell transplantation, n (%) | 16 (1) | 5 (3) | 1 (< 1) | 0 | 0 | 1 (< 1) | 20 (4) | 1 (< 1) |
| Tyrosine kinase inhibitor, n (%) | 420 (37) | 50 (29) | 65 (26) | 0 | 0 | 0 | 36 (7) | 499 (92) |
| No therapy, n (%) | 1 (< 1) | 7 (3) | 0 | 0 | 1 | 1 | 6 (1) | |
| Unknown/not available, n (%) | 37 (3) | 3 (2) | 32 (13) | 2 (1) | 4 (2) | 12 (5) | 33 (7) | 21 (4) |
| Stem cell transplantation salvage by CML phase at time of transplantation, n (%)* | 74 (39) | 42 (22) | 75 (39) | 0 | 2 (1) | 28 (15) | 114 (60) | 47 (25) |
191 patients received allogeneic stem cell transplantation as salvage therapy.